NCT06439771View on ClinicalTrials.gov

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 23, 2024

Primary Completion Date

July 30, 2026

Study Completion Date

July 29, 2028

Conditions
Locally Advanced or Metastatic Breast Cancer
Interventions
DRUG

YL202 should be intravenously infused

For each patient, YL202 should be intravenously infused over 60±10 min.

Trial Locations (1)

250117

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

MediLink Therapeutics (Suzhou) Co., Ltd.

INDUSTRY